# Advisory Committee on Immunization Practices: Meeting
In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following committee meeting:
*Name: * Advisory Committee on Immunization Practices (ACIP).
*Times and Dates: * 8:30 a.m.-6 p.m., February 16, 2000.8 a.m.-5 p.m., February 17, 2000.
*Place: * Atlanta Marriott Century Center, 2000 Century Boulevard, NE., Atlanta, Georgia 30345-3377.
*Status: * Open to the public, limited only by the space available.
*Purpose: * The Committee is charged with advising the Director, CDC, on the appropriate uses of immunizing agents.In addition, under 42 U.S.C. § 1396s, the Committee is mandated to establish and periodically review and, as appropriate, revise the list of vaccines for administration to vaccine-eligible children through the Vaccines for Children (VFC) program, along with schedules regarding the appropriate periodicity, dosage, and contraindications applicable to the vaccines.
*Matters To Be Discussed: * The agenda will include a discussion on the revision of the ACIP recommendations for the pneumococcal conjugate vaccine; cost benefit analysis of the pneumococcal conjugate vaccine; update on the revision of the general recommendations; update on the adult immunization recommendations; update on the standing orders for adult immunization, adverse events after use of yellow fever vaccine; prevention of pneumococcal disease and vaccination in persons 50-64 years of age; use of DTaP as the fifth dose following four doses of DTaP; 2000-2001 control and prevention of influenza recommendations; update of 1999-2000 influenza season and vaccine strain selection process; lyme disease vaccine update: trials in children, alternate dosing, boosters, VAERS data; effect of changes in hepatitis B immunization recommendations due to concerns about thimerosal; 2-dose adolescent hepatitis B vaccination; Vaccines for Children vote on FDA approved schedule for 2-dose adolescent hepatitis B vaccination, inactivated polio virus vaccine, pneumococcal vaccine, and rotavirus vaccine; high-speed needle-free jet injectors and mass vaccination for pandemic influenza or bioterrorism; update on the bioterrorism and anthrax work group; an update from the Food and Drug Administration; update from the National Center for Infectious Diseases; update from the National Immunization Program; update from the Vaccine Injury Compensation Program; update from the National Vaccine Program; review of immunogenicity of Pentacel® and update on the Infanrix® vaccine. Other matters of relevance among the committee's objectives may be discussed.
Agenda items are subject to change as priorities dictate.
**CONTACT PERSON FOR MORE INFORMATION:**
Gloria A. Kovach, Program Analyst, Epidemiology and Surveillance Division,National Immunization Program, CDC, 1600 Clifton Road, NE., m/s E61, Atlanta, Georgia 30333. Telephone 404/639-8096.
The Director, Management Analysis and Services office has been delegated the authority to sign *Federal Register* notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Dated: January 20, 2000.
Carolyn J. Russell,
Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).